Kolltan Pharmaceuticals announces KTN0158 preclinical data at ESMO 2015

Kolltan Pharmaceuticals, Inc. today announced the presentation of data from a preclinical study evaluating KTN0158 in dogs with spontaneous mast cell tumors. Source link